Abstract
Purpose A growing body of evidence suggests a protective role for high-density lipoprotein (HDL) in the development and progression of sepsis. However, evidence favoring causality between HDL and sepsis remains limited. Here we investigated, by using Mendelian randomization (MR), the potential causal link between HDL particle concentration or HDL-related proteins, and the risk of developing sepsis.
Methods Two-sample MR analyses were conducted to investigate association between genetically-influenced HDL particle concentration, HDL-related proteins, and the risk of sepsis. We utilized a genome-wide association study (GWAS) comprising 10,154 sepsis cases and 452,764 controls as outcome. Inverse-variance weighted (IVW) analyses were employed as primary analyses. Protein-protein interaction (PPI) network analyses were used to identify key regulators for concentration of HDL particles and ApoA1.
Results Based on the IVW analyses, we found evidence for an association between genetically-influenced higher HDL particle concentration and lower risk of sepsis (odds ratio (OR): 0.86, 95% confidential interval (CI): 0.77-0.96). Similarly, genetically-influenced higher ApoA1 concentration was associated with a lower risk of sepsis (OR: 0.90, 95% CI: 0.85 - 0.96). Through PPI network analyses, we identified cholesteryl ester transfer protein (CETP) as one of the key players in regulating the concentration of HDL particles and ApoA1, and sepsis risk as such.
Conclusion Our MR study provides evidence for an inverse relationship between HDL particle concentration or ApoA1, and the susceptibility to sepsis. We anticipate that CETP inhibitory strategies may increase HDL particle concentration and apoA1 to lower sepsis susceptibility and potentially prevent the risks associated with sepsis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
GWAS summary data used for the present study were extracted from the Integrative Epidemiology Unit (IEU) database (https://gwas.mrcieu.ac.uk/), which is a public database containing summary-level data from over 42,000 GWAS summary datasets.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
